On October 19, 2026 Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, reported the closing of an oversubscribed €120 million ($135 million) Series D financing. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), and Neva SGR (Intesa Sanpaolo Group). Nouscom’s other existing international life sciences investors, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures, all participated in the round. The strong demand for the round reflects investor conviction in Nouscom’s pipeline and recently published clinical data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the Series D round will fund the advancement of NOUS-209, an investigational off-the-shelf neoantigen-based cancer immunotherapy, through a single, global, registration-enabling clinical trial for cancer interception in Lynch Syndrome (LS) carriers, for which FDA has granted Fast Track designation.

The financing coincides with a presentation of long-term cancer interception data from a Phase 1b/2 trial of NOUS-209 in LS carriers, to be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress by the study’s principal investigator Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center. ESMO (Free ESMO Whitepaper) is taking place in Madrid, Spain on 23-27 October 2026. Details of the presentation are below.

The abstract, published by ESMO (Free ESMO Whitepaper), reports that all evaluable LS carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer, as determined by colonoscopy, after years 1 and 2 (n=43; n=17, respectively), representing an encouraging signal of durable clinical activity consistent with a treatment effect relative to the expected incidence in LS carriers. These data were strengthened by broad, potent, and durable anti-neoantigen T-cell responses driven by NOUS-209 that were further enhanced following annual re-treatment.

"Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery", said Marina Udier, Ph.D., Chief Executive Officer of Nouscom. "We built Nouscom to change that equation. This financing, alongside the data we are presenting at ESMO (Free ESMO Whitepaper), puts us closer to a world where cancer is stopped before it starts. I am grateful to our new and existing investors for backing that conviction, and to the team behind NOUS-209."

"This significant financing reflects the confidence of our investors in Nouscom’s vision, team and the transformative potential of cancer interception," said Göran Ando, M.D., Independent Chair of the Board of Nouscom. "With this backing, we are well positioned to accelerate NOUS-209’s clinical development and our commitment to those living with Lynch Syndrome. I am delighted to welcome our new investors, whose support further strengthens Nouscom as we enter this next chapter."

Dr. Hakan Goker, Managing Director and Head of Biotechnology Investments at M Ventures, said: "What sets Nouscom apart is its unique cancer interception approach and the platform that enables it. Maturing clinical evidence and a regulatory-aligned path into a registration-enabling trial in such an unchartered space is a rare combination for a private biotech company and the commitment of the investor syndicate underpins this deep conviction."

Angelini Industries joins as a new investor, having followed Nouscom since its Series C round through Angelini Ventures, which also participated in the Series D. "Angelini Industries is becoming an increasingly innovation-driven group competing on a global scale, bringing together the search for companies set to shape the future of healthcare with the research and pharmaceutical assets of our industrial heritage." said Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries, and VP of Angelini Investments. "We see significant potential in Nouscom’s pioneering approach to cancer prevention in Lynch Syndrome and we are proud to support its outstanding team."

Details of the Presentation:

Title: Safety and Immunogenicity of Re-vaccination with Nous-209: a neoantigen vaccine for cancer interception in Lynch syndrome carriers

Presenter: Eduardo Vilar-Sanchez, M.D., Ph.D., The University of Texas MD Anderson Cancer Center

Abstract #: 3438O

Date/Time: Sunday 25 October, 15:15hrs CEST

Location: Granada Auditorium, Hall 4

The Phase 1b/2 clinical trial of NOUS-209 in LS carriers (NCT05078866) was a collaborative effort between the National Cancer Institute’s Cancer Prevention Clinical Trials Network (CP-CTNet) and the iCAN-PREVENT consortium at UT MD Anderson. The NCI, part of the National Institutes of Health, provided primary funding through Award Number UG1-CA-242609, with additional support from the Data Management, Auditing, and Coordination Center (grant U24CA242637).

(Press release, NousCom, OCT 19, 2026, View Source;utm_medium=rss&utm_campaign=nouscom-raises-e120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo [SID1234673560])